The vision of saniva diagnostics GmbH is to establish a screening test for neurodegenerative diseases on the market for the first time. The screening test is inexpensive, standardized and can be carried out in a short space of time, making it easy to integrate into everyday clinical practice.

The special feature of the NeuroMex medical device is that patients with incipient neurodegeneration can already be identified. At this stage, the patients themselves are usually still asymptomatic. Comparable diagnostic approaches still reach their limits at this early stage. The reason for this is that the main symptoms usually only become detectable when the degeneration of the brain cell has already progressed.

There can be up to 10 years between the asymptomatic phase and the disclosure of the main symptoms.

The early detection of incipient diseases opens up the possibility of applying more efficient therapy methods and thus positively influencing the course of the disease in the long term.

According to the company’s motto: “CATCH EARLY & TREAT BETTER!”

The screening instrument developed by saniva diagnostics GmbH lays the foundation for the application of innovative therapy methods that cannot be used according to the current state of the art because of the usual diagnostics in the advanced stage of the disease. In this way, saniva diagnostics GmbH is not only opening up a new market, but also offering an instrument that can potentially help with research into new therapy methods.